Michael Serenko

712 total citations
10 papers, 480 citations indexed

About

Michael Serenko is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Michael Serenko has authored 10 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 5 papers in Experimental and Cognitive Psychology and 4 papers in Psychiatry and Mental health. Recurrent topics in Michael Serenko's work include Treatment of Major Depression (8 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Tryptophan and brain disorders (3 papers). Michael Serenko is often cited by papers focused on Treatment of Major Depression (8 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Tryptophan and brain disorders (3 papers). Michael Serenko collaborates with scholars based in United States, Japan and France. Michael Serenko's co-authors include Atul R. Mahableshwarkar, Paula L. Jacobsen, Yinzhong Chen, Madhukar H. Trivedi, Zhen Zhao, Ronald Lee, Grace Chen, Grace Chen, Hongjie Deng and Benjamin Wu and has published in prestigious journals such as PLoS ONE, Psychopharmacology and Journal of Immunological Methods.

In The Last Decade

Michael Serenko

10 papers receiving 455 citations

Peers

Michael Serenko
Alessandra Signoretti Italy
Ursula Reichenpfader United States
G. Laux Germany
J. Søgaard Denmark
Michaela Strobelberger United States
Trisha L. Houser United States
Alan Lenox‐Smith United Kingdom
B G Pollock United States
Aleksandra Dragičević Germany
M. Stabl Switzerland
Alessandra Signoretti Italy
Michael Serenko
Citations per year, relative to Michael Serenko Michael Serenko (= 1×) peers Alessandra Signoretti

Countries citing papers authored by Michael Serenko

Since Specialization
Citations

This map shows the geographic impact of Michael Serenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Serenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Serenko more than expected).

Fields of papers citing papers by Michael Serenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Serenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Serenko. The network helps show where Michael Serenko may publish in the future.

Co-authorship network of co-authors of Michael Serenko

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Serenko. A scholar is included among the top collaborators of Michael Serenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Serenko. Michael Serenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Block, Geoffrey A., Glenn M. Chertow, John T. Sullivan, et al.. (2019). An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE. 14(3). e0213774–e0213774. 14 indexed citations
2.
Kroenke, Mark A., Hongjie Deng, Raju Subramanian, et al.. (2017). Clinical immunogenicity of the d -amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. Journal of Immunological Methods. 445. 37–44. 15 indexed citations
3.
Jacobsen, Paula L., et al.. (2015). A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder. The Journal of Clinical Psychiatry. 76(5). 575–582. 83 indexed citations
4.
Mahableshwarkar, Atul R., Paula L. Jacobsen, Michael Serenko, Yinzhong Chen, & Madhukar H. Trivedi. (2015). A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder. The Journal of Clinical Psychiatry. 76(5). 583–591. 72 indexed citations
5.
Mahableshwarkar, Atul R., Paula L. Jacobsen, Yinzhong Chen, Michael Serenko, & Madhukar H. Trivedi. (2015). A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology. 232(12). 2061–2070. 84 indexed citations
6.
Chen, Grace, et al.. (2015). Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. The Journal of Clinical Pharmacology. 55(6). 671–679. 23 indexed citations
7.
Mahableshwarkar, Atul R., Paula L. Jacobsen, Michael Serenko, & Yinzhong Chen. (2014). A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Human Psychopharmacology Clinical and Experimental. 29(1). 64–72. 37 indexed citations
8.
Jacobsen, Paula L., et al.. (2013). Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder. International Clinical Psychopharmacology. 29(1). 36–44. 57 indexed citations
9.
Chen, Grace, et al.. (2013). Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant. Clinical Drug Investigation. 33(10). 727–736. 78 indexed citations
10.
Wang, Ying, George G. Nomikos, Aziz Karim, et al.. (2013). Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study. Clinical Pharmacology in Drug Development. 2(4). 298–309. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Signoretti Breakdown of academic impact, for papers by Ursula Reichenpfader Breakdown of academic impact, for papers by G. Laux Breakdown of academic impact, for papers by J. Søgaard Breakdown of academic impact, for papers by Michaela Strobelberger Breakdown of academic impact, for papers by Trisha L. Houser Breakdown of academic impact, for papers by Alan Lenox‐Smith Breakdown of academic impact, for papers by B G Pollock Breakdown of academic impact, for papers by Aleksandra Dragičević Breakdown of academic impact, for papers by M. Stabl
Rankless by CCL
2026